Amyotrophic Lateral SclerosisGAITALSNCT01874808
From Movement Preparation to Gait Execution in ALS
An observational study of Amyotrophic Lateral Sclerosis, run by Institut National de la Santé Et de la Recherche Médicale, France at 1 site in France.
Trial summary
This research program will focus on gait initiation and postural control in Amyotrophic Lateral Sclerosis (ALS) patients, by comparing patients with vs without postural instability (but also in comparison to controls), by using a multidisciplinary approach which combines neurophysiological and neuroimaging analyses. Read more about this study
- Who is it for?
- Ages 18 to 75 yearsHealthy volunteers can take part
- Conditions the study is for
- Amyotrophic Lateral Sclerosis
- How many people
- 59 participants
- Where
- 1 siteFrance
- Study dates
- 21 Jun 2013to 21 Dec 2015
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: ALS patients with motor deficit with or without postural instability
Who may be able to join
- Between 18 (exclusive) and 75 (inclusive) years old
- With a defined, probable or laboratory possible ALS according to El Escorial18
- With a disease duration between 3 months (inclusive) and 5 years (exclusive)
- Able to walk at least 10 meters without an aid and to perform the foot-tapping task
- Right handed
- Able to understand thoroughly the given information; able to sign the informed consent form (signature of spouse or family relative or acceptable third party is acceptable if the patient is physically unable to sign)
- With a social insurance
Who cannot join
- Patients with a fronto temporal dementia (according to Neary' criteria)
- Patients with any concomitant life-threatening disease or any disease or impairment likely to interfere with functional assessment
- Patients with any major evolving psychiatric disorder or major anxiety disorder according to DSM-IV criteria (APA, 1996)
- Patients with contraindications for the MRI scan
Trial locations and contacts
1 site in 1 country.
France1 site
Hôpital Pitié-Salpétrière, Département des Maladies du Système Nerveux 47-83 Boulevard de l'Hôpital
Paris, 75013
About this study
Official title: From Movement Preparation to Gait Execution in ALS: : Combined Neurophysiological and Neuroimaging Approaches
This research program will focus on gait initiation and postural control in Amyotrophic Lateral Sclerosis (ALS) patients, by comparing patients with vs without postural instability (but also in comparison to controls), by using a multidisciplinary approach which combines neurophysiological and neuroimaging analyses.
After clinical evaluation, two groups of ALS patients, defined upon the feature of postural instability, and one group of healthy subjects (n=25 for each group of patients and 20 for healthy subjects) will be included in the study.
Read more
The neurophysiological evaluation will be performed through a gait initiation assessment, which will alow us to collect biomechanical and electromyographical data, such as the braking index.
The neuroradiological evaluation will include first an fMRI analysis, a study of specific circuits in networks will be performed which will provide the first description of neural network dynamics associated with the preparation and execution of movement in ALS patients.
The investigators major research hypothesis is:
- By comparing patients with vs without postural instability, but also in comparison to controls, the investigators main research neurophysiological hypothesis is that patients with postural instability will display an impaired braking.
- This impaired braking could be partly explained by a dysfunction and/or lesion of the basal ganglia and brain stem structures, corresponding to the investigators main neuroradiological hypothesis.
Read the detailed description
Compared to other movement disorders, such as Parkinson Disease (PD), the mechanisms of movement impairment in Amyotrophic Lateral Sclerosis (ALS) have not been a focus of great interest. It is at least partly related to the classical assumption that impairment of movement in ALS simply reflects a dysfunction of the final motor pathways. However, the concept that ALS purely involves upper and lower motor neuron has been definitively challenged. Accumulating evidence for the concept that ALS is a multisystem degenerative disease is supported by histological, neurophysiological and neuroimaging studies. Clinically, lower limb stiffness is associated with extrapyramidal rigidity and postural instability in 69% of ALS patients. These latter may also display abnormalities of movement initiation impairing walking, such as gait initiation failure, usually reported in PD patients. All these data support the hypothesis that some balance troubles in ALS patients may result from an additional dysfunction and/or lesion of the basal ganglia circuitry and/or of its output structures, such as the cortex or the midbrain.
In PD patients, which represent a model of basal ganglia system dysfunction, length and velocity of the first step during gait initiation are known to be reduced and improved by dopaminergic therapy whereas postural instability is less sensitive to the treatment suggesting the involvement of other brain structures dysfunction and/or lesion. One way to evaluate the postural control during the gait initiation process is to measure the vertical velocity of the centre of gravity by using a force platform. In healthy adults, during the single support phase, a forward fall of the centre of gravity occurs and is actively reversed by the stance leg soleus muscle activation prior foot contact. In parkinsonian patients with postural instability, this phenomenon, called active braking, is altered. It is assumed that this postural instability results from additional lesions and/or dysfunction in the basal ganglia output structures, especially in the midbrain, containing the pedunculopontine nucleus and the mesencephalic locomotor region, two structures known to participate to the control of locomotion and posture in animals.
This research program will focus on gait initiation and postural control in ALS patients, by comparing patients with vs without postural instability (but also in comparison to controls), by using a multidisciplinary approach which combines neurophysiological and neuroimaging analyses.
After clinical evaluation, two groups of ALS patients, defined upon the feature of postural instability, and one group of healthy subjects (n=25 for each group of patients and 20 for healthy subjects) will be included in the study.
The neurophysiological evaluation will be performed through a gait initiation assessment, which will alow us to collect biomechanical and electromyographical data, such as the braking index.
The neuroradiological evaluation will include first an fMRI analysis. A study of specific circuits in networks will be performed which will provide the first description of neural network dynamics associated with the preparation and execution of movement in ALS patients.
If the investigators get a deeper understanding of the neural substrates underlying the hypothetical impairment of gait initiation and postural control, the investigators will then be able to develop adequate therapeutical strategies (pharmacological interventions, surgical therapies, rehabilitation programs) aimed at improving movement preparation and gait execution in ALS patients
- Conditions
- Amyotrophic Lateral Sclerosis
- Keywords
- movement preparation, gait, gait initiation, postural control, neuroimaging
- Medical subject headings
- Amyotrophic Lateral Sclerosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Healthy | Healthy | |
| ALS with postural instability | ALS with postural instability | |
| ALS without postural instability | ALS without postural instability |
What is being measured
The primary outcome is the main question the study is designed to answer.
Neurophysiological evaluation (braking index)
Braking index
Measured: 1 day of the experiment
Secondary outcomes (1)
Evaluation in neuroimaging
FMRI analysis
Measured: 1 day of the experiment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Jun 2013 (estimated)
- Study start21 Jun 2013
- Primary completionDec 2015
- Study completion21 Dec 2015
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Amyotrophic Lateral SclerosisStudies of the same condition, open and under way.
- More trials run by Institut National de la Santé Et de la Recherche Médicale, FranceThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Other
- Enrolment
- 59 participants (actual)
Sponsor and investigators
- Sponsor type
- Other government
- Collaborators
- Université Paris Ouest-EA 2931-CEntre de Recherches sur le Sport et le Mouvement
- Responsible party
- Sponsor
- Investigators
- Pierre François Pradat, MD, Principal investigator, Hôpital Pitié-Salpétrière, Département des Maladies du Système Nerveux 47-83 Boulevard de l'Hôpital 75013 Paris France
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01874808
- Sponsor's protocol ID
- GAITALS-C12-13
- Other IDs
- 2012-A01247-36
- Acronym
- GAITALS
- Status last verified
- Aug 2021
- First submitted
- 20 Mar 2013
- Last updated
- 18 Nov 2025
- Results posted
- No
- Data monitoring committee
- Yes
Publications
Abidi M, de Marco G, Grami F, Termoz N, Couillandre A, Querin G, Bede P, Pradat PF. Neural Correlates of Motor Imagery of Gait in Amyotrophic Lateral Sclerosis. J Magn Reson Imaging. 2021 Jan;53(1):223-233. doi: 10.1002/jmri.27335. Epub 2020 Sep 7.
PubMed 32896088Abidi M, de Marco G, Couillandre A, Feron M, Mseddi E, Termoz N, Querin G, Pradat PF, Bede P. Adaptive functional reorganization in amyotrophic lateral sclerosis: coexisting degenerative and compensatory changes. Eur J Neurol. 2020 Jan;27(1):121-128. doi: 10.1111/ene.14042. Epub 2019 Aug 13.
PubMed 31310452
Study at a glance
From the registry record, last updated by the sponsor on 18 Nov 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- From Movement Preparation to Gait Execution in ALS: : Combined Neurophysiological and Neuroimaging Approaches
- ClinicalTrials.gov ID
- NCT01874808
- Acronym / sponsor ID
- GAITALS / GAITALS-C12-13
- Conditions
- Amyotrophic Lateral Sclerosis
- Keywords
- movement preparation, gait, gait initiation, postural control, neuroimaging
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 59 participants (actual)
- Lead sponsor
- Institut National de la Santé Et de la Recherche Médicale, FranceOther government
- Collaborators
- Université Paris Ouest-EA 2931-CEntre de Recherches sur le Sport et le Mouvement
- Study start
- 21 Jun 2013 (actual)
- Primary completion
- Dec 2015 (actual)
- Study completion
- 21 Dec 2015 (actual)
- First posted
- 11 Jun 2013 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This research program will focus on gait initiation and postural control in Amyotrophic Lateral Sclerosis (ALS) patients, by comparing patients with vs without postural instability (but also in comparison to controls), by using a multidisciplinary approach which combines neurophysiological and neuroimaging analyses.
After clinical evaluation, two groups of ALS patients, defined upon the feature of postural instability, and one group of healthy subjects (n=25 for each group of patients and 20 for healthy subjects) will be included in the study.
The neurophysiological evaluation will be performed through a gait initiation assessment, which will alow us to collect biomechanical and electromyographical data, such as the braking index.
The neuroradiological evaluation will include first an fMRI analysis, a study of specific circuits in networks will be performed which will provide the first description of neural network dynamics associated with the preparation and execution of movement in ALS patients.
The investigators major research hypothesis is:
- By comparing patients with vs without postural instability, but also in comparison to controls, the investigators main research neurophysiological hypothesis is that patients with postural instability will display an impaired braking.
- This impaired braking could be partly explained by a dysfunction and/or lesion of the basal ganglia and brain stem structures, corresponding to the investigators main neuroradiological hypothesis.
Detailed description
Compared to other movement disorders, such as Parkinson Disease (PD), the mechanisms of movement impairment in Amyotrophic Lateral Sclerosis (ALS) have not been a focus of great interest. It is at least partly related to the classical assumption that impairment of movement in ALS simply reflects a dysfunction of the final motor pathways. However, the concept that ALS purely involves upper and lower motor neuron has been definitively challenged. Accumulating evidence for the concept that ALS is a multisystem degenerative disease is supported by histological, neurophysiological and neuroimaging studies. Clinically, lower limb stiffness is associated with extrapyramidal rigidity and postural instability in 69% of ALS patients. These latter may also display abnormalities of movement initiation impairing walking, such as gait initiation failure, usually reported in PD patients. All these data support the hypothesis that some balance troubles in ALS patients may result from an additional dysfunction and/or lesion of the basal ganglia circuitry and/or of its output structures, such as the cortex or the midbrain.
In PD patients, which represent a model of basal ganglia system dysfunction, length and velocity of the first step during gait initiation are known to be reduced and improved by dopaminergic therapy whereas postural instability is less sensitive to the treatment suggesting the involvement of other brain structures dysfunction and/or lesion. One way to evaluate the postural control during the gait initiation process is to measure the vertical velocity of the centre of gravity by using a force platform. In healthy adults, during the single support phase, a forward fall of the centre of gravity occurs and is actively reversed by the stance leg soleus muscle activation prior foot contact. In parkinsonian patients with postural instability, this phenomenon, called active braking, is altered. It is assumed that this postural instability results from additional lesions and/or dysfunction in the basal ganglia output structures, especially in the midbrain, containing the pedunculopontine nucleus and the mesencephalic locomotor region, two structures known to participate to the control of locomotion and posture in animals.
This research program will focus on gait initiation and postural control in ALS patients, by comparing patients with vs without postural instability (but also in comparison to controls), by using a multidisciplinary approach which combines neurophysiological and neuroimaging analyses.
After clinical evaluation, two groups of ALS patients, defined upon the feature of postural instability, and one group of healthy subjects (n=25 for each group of patients and 20 for healthy subjects) will be included in the study.
The neurophysiological evaluation will be performed through a gait initiation assessment, which will alow us to collect biomechanical and electromyographical data, such as the braking index.
The neuroradiological evaluation will include first an fMRI analysis. A study of specific circuits in networks will be performed which will provide the first description of neural network dynamics associated with the preparation and execution of movement in ALS patients.
If the investigators get a deeper understanding of the neural substrates underlying the hypothetical impairment of gait initiation and postural control, the investigators will then be able to develop adequate therapeutical strategies (pharmacological interventions, surgical therapies, rehabilitation programs) aimed at improving movement preparation and gait execution in ALS patients
Study design
- Observational model
- Other
- Time perspective
- Other
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Healthy | – | –Healthy |
| ALS with postural instability | – | –ALS with postural instability |
| ALS without postural instability | – | –ALS without postural instability |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- ALS patients with motor deficit with or without postural instability
Key inclusion criteria (7 listed)
- Between 18 (exclusive) and 75 (inclusive) years old
- With a defined, probable or laboratory possible ALS according to El Escorial18
- With a disease duration between 3 months (inclusive) and 5 years (exclusive)
- Able to walk at least 10 meters without an aid and to perform the foot-tapping task
- Right handed
Key exclusion criteria (4 listed)
- Patients with a fronto temporal dementia (according to Neary' criteria)
- Patients with any concomitant life-threatening disease or any disease or impairment likely to interfere with functional assessment
- Patients with any major evolving psychiatric disorder or major anxiety disorder according to DSM-IV criteria (APA, 1996)
- Patients with contraindications for the MRI scan
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Neurophysiological evaluation (braking index)
Time frame: 1 day of the experiment
Braking index
1 secondary outcome
Evaluation in neuroimaging
Time frame: 1 day of the experiment
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Nov 2025.
- Results publication: PubMed 32896088Abidi M, de Marco G, Grami F, Termoz N, Couillandre A, Querin G, Bede P, Pradat PF. Neural Correlates of Motor Imagery of Gait in Amyotrophic Lateral Sclerosis. J Magn Reson Imaging. 2021 Jan;53(1):223-233. doi: 10.1002/jmri.27335. Epub 2020 Sep 7.
- Results publication: PubMed 31310452Abidi M, de Marco G, Couillandre A, Feron M, Mseddi E, Termoz N, Querin G, Pradat PF, Bede P. Adaptive functional reorganization in amyotrophic lateral sclerosis: coexisting degenerative and compensatory changes. Eur J Neurol. 2020 Jan;27(1):121-128. doi: 10.1111/ene.14042. Epub 2019 Aug 13.
Related trials for Amyotrophic Lateral Sclerosis
Not yet recruitingPhase 1
A Study of Single Ascending Doses of NI112 in Adults With Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis (ALS)
Recruiting
MindEx: A Novel, Multifocal, Cognitive Brain-Machine Interface System
Paralysis; Quadriplegic, Quadraplegia
RecruitingPhase 1/2
Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS
Amyotrophic Lateral Sclerosis
RecruitingObservational study
Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
Frontotemporal Dementia, Amyotrophic Lateral Sclerosis
Recruiting
Anticipated Patient and Caregiver Burden
Amyotrophic Lateral Sclerosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Pierre François Pradat, MD principal investigator
Hôpital Pitié-Salpétrière, Département des Maladies du Système Nerveux 47-83 Boulevard de l'Hôpital 75013 Paris France
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Amyotrophic Lateral Sclerosis, run by Institut National de la Santé Et de la Recherche Médicale, France at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Neurophysiological evaluation (braking index) (time frame: 1 day of the experiment). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01874808, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Nov 2025.